Results
|
|
8081.
|
Targeting newly identified ERβ/TGF-β1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma. [electronic resource] by
- Song, Wenbin
- He, Dalin
- Chen, Yule
- Yeh, Chiuan-Ren
- Hsu, Iawen
- Huang, Qingbo
- Zhang, Xu
- Chang, Luke Sien-Shih
- Zuo, Li
- Chen, Jiasheng
- Doersch, Karen M
- Chang, Chawnshang
- Li, Lei
- Yeh, Shuyuan
Producer: 20190823
In:
Molecular oncology vol. 12
Availability: No items available.
|
|
|
8082.
|
|
|
|
8083.
|
|
|
|
8084.
|
|
|
|
8085.
|
|
|
|
8086.
|
|
|
|
8087.
|
|
|
|
8088.
|
|
|
|
8089.
|
|
|
|
8090.
|
|
|
|
8091.
|
|
|
|
8092.
|
|
|
|
8093.
|
|
|
|
8094.
|
|
|
|
8095.
|
|
|
|
8096.
|
|
|
|
8097.
|
|
|
|
8098.
|
|
|
|
8099.
|
|
|
|
8100.
|
|